Keytruda and Chemotherapy in Advanced Endometrial Cancer
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- August 2, 2023
- Reading time: 1 minute
On June 3, 2023, Dr. Ramez N. Eskander and colleagues from the University of California San Diego published the results of the Phase 3 NRG-GY018 trial in The New England Journal of Medicine. The study evaluated the addition of Keytruda (pembrolizumab) to standard first-line chemotherapy for patients with recurrent or advanced endometrial cancer.
Study Design: The NRG-GY018 trial enrolled 816 patients with Stage III, IVA, IVB, or recurrent endometrial cancer. Participants were randomized 1:1 into two groups:
- Keytruda Group: Keytruda plus chemotherapy (up to 6 cycles every three weeks), followed by Keytruda monotherapy as maintenance (up to 14 cycles every six weeks).
- Placebo Group: Standard chemotherapy plus placebo.
The primary endpoint was progression-free survival (PFS), stratified by mismatch-repair-deficient (dMMR) or mismatch-repair-proficient (pMMR) status.
Clinical Outcomes: The trial results showed significant improvements in PFS for the Keytruda group:
- dMMR Patients: The 12-month PFS rate was 74% in the Keytruda group compared to 38% in the placebo group.
- pMMR Patients: The median PFS was 13.1 months in the Keytruda group versus 8.7 months in the placebo group.
Conclusion: Based on the results of the NRG-GY018 trial, Dr. Ramez N. Eskander and the research team concluded that adding Keytruda to first-line chemotherapy significantly improves progression-free survival in patients with recurrent or advanced endometrial cancer.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312
- Clinical Trial Medications
- Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1